<DOC>
	<DOCNO>NCT01613287</DOCNO>
	<brief_summary>This clinical investigation medical device trial examine safety efficacy TheraSorb® Ig flex adsorber treatment ( add-on conventional treatment ) use exclusively LIFE 18® apheresis system extracorporeal application IA therapy ( 5 treatment ) perform 5 8 consecutive day patient Idiopathic Pulmonary Arterial Hypertension WHO functional classification III .</brief_summary>
	<brief_title>Proof Concept Study IMMUNOadsorption Therapy Patients With Idiopathic Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Able understand willing sign Informed Consent Form age &gt; 18 &lt; 80 year time inform consent Idiopathic pulmonary arterial hypertension diagnose right heart catheter WHO functional classification III Application conventional IPAH therapy , stable prior 8 week Able perform 6minutewalk test ( MWT ) Negative pregnancy test ( βHCG ) start trial appropriate contraception throughout trial woman childbearing potential . Pregnancy and/or lactation PAH cause permit inclusion criterion , e.g . concomitantly portal hypertension , complex congenital heart disease , reverse shunt , HIV infection , suspect pulmonary venoocclusive disease Contraindication right heart catheterization Any change diseasetargeted therapy within 8 week prior inclusion Walking impairment due cause IPAH would preclude performance 6MWT Any patient receive investigational medication within 8 week prior start trial schedule receive another investigational drug course trial visit V1 V9 Known intolerance immunoadsorption general one excipients ( e.g . sheep antibody agarose ) support agent Hemoglobin concentration &lt; 75 % low limit normal Systolic blood pressure &lt; 85 mmHg Lack compliance similar reason , judgment Investigator , preclude satisfactory participation trial Concurrent severe uncontrolled medical disease ( i.e . uncontrolled diabetes , congestive heart failure , myocardial infarction within 6 month prior study , unstable uncontrolled hypertension , chronic renal disease , active uncontrolled generalize viral , bacterial and/ mycotic infection ) assessment treat Investigator could compromise patient safety participation study Drug alcohol abuse within last 5 year Hypercoagulability Known severe immunodeficiency ( e.g . AIDS ) Severe lung disease : FEV1/FVC &lt; 50 % , total capacity &lt; 60 % normal value Indications prohibit transient anticoagulation use Heparin and/or ACDAsolutions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>TheraSorb</keyword>
	<keyword>immunoadsorption</keyword>
</DOC>